
    
      This is a multicenter open-label randomized study for the early treatment of pneumonia due to
      SARS-COV2 with transfusion of convalescent plasma.

      Patients with SARS-CoV2 pneumonia not requiring mechanical ventilation (both non invasive and
      invasive) will be randomized to receive or not convalescent plasma.

      Patients in the plasma group will receive 200-300 ml of plasma collected by recovered
      patients with previous diagnosis of COVID19, plus standard therapy; Patients in the control
      group will receive the standard therapy. A rescue therapy will be allowed in case of clinical
      worsening.

      Patients will be followed until day n30 from randomization.
    
  